These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26091797)

  • 21. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
    Butchi NB; Du M; Peterson KE
    Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7.
    Hayashi T; Gray CS; Chan M; Tawatao RI; Ronacher L; McGargill MA; Datta SK; Carson DA; Corr M
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2764-9. PubMed ID: 19188597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.
    Gotoh K; Tanaka Y; Nishikimi A; Nakamura R; Yamada H; Maeda N; Ishikawa T; Hoshino K; Uruno T; Cao Q; Higashi S; Kawaguchi Y; Enjoji M; Takayanagi R; Kaisho T; Yoshikai Y; Fukui Y
    J Exp Med; 2010 Apr; 207(4):721-30. PubMed ID: 20231379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen receptor signals rescue B cells from TLR tolerance.
    Poovassery JS; Vanden Bush TJ; Bishop GA
    J Immunol; 2009 Sep; 183(5):2974-83. PubMed ID: 19648281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
    Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
    Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway.
    Davidson S; Kaiko G; Loh Z; Lalwani A; Zhang V; Spann K; Foo SY; Hansbro N; Uematsu S; Akira S; Matthaei KI; Rosenberg HF; Foster PS; Phipps S
    J Immunol; 2011 May; 186(10):5938-48. PubMed ID: 21482736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation.
    Ota Y; Inagaki R; Nagai Y; Hirose Y; Murata M; Yamamoto S
    BMC Immunol; 2024 Jul; 25(1):48. PubMed ID: 39054418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
    Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
    J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
    Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
    Front Immunol; 2020; 11():580974. PubMed ID: 33262759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms.
    Poovassery JS; Bishop GA
    J Immunol; 2012 Aug; 189(4):1757-64. PubMed ID: 22786773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptor 7 agonist induces hypoplasia of the biliary system in a neonatal mouse model.
    Huang YH; Shih HH; Tiao MM; Huang CC; Kuo KC; Huang FC; Yang YL; Chuang JH
    J Microbiol Immunol Infect; 2018 Apr; 51(2):166-173. PubMed ID: 27590984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.
    Gautier G; Humbert M; Deauvieau F; Scuiller M; Hiscott J; Bates EE; Trinchieri G; Caux C; Garrone P
    J Exp Med; 2005 May; 201(9):1435-46. PubMed ID: 15851485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.
    Hayashi T; Cottam HB; Chan M; Jin G; Tawatao RI; Crain B; Ronacher L; Messer K; Carson DA; Corr M
    Am J Physiol Regul Integr Comp Physiol; 2008 Jul; 295(1):R123-32. PubMed ID: 18480244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells.
    Sriram U; Xu J; Chain RW; Varghese L; Chakhtoura M; Bennett HL; Zoltick PW; Gallucci S
    PLoS One; 2014; 9(1):e87668. PubMed ID: 24489947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.
    Pinhal-Enfield G; Ramanathan M; Hasko G; Vogel SN; Salzman AL; Boons GJ; Leibovich SJ
    Am J Pathol; 2003 Aug; 163(2):711-21. PubMed ID: 12875990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation.
    Diao Y; Wang X; Wan Y; Zhong J; Gao D; Liu Y; Gao N; Li W; Liu B; Huang X; Jin Z; Peng B; Wang Z; Fu L; Chen S; Jin G
    Oncol Rep; 2016 Feb; 35(2):793-800. PubMed ID: 26718332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
    Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
    Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.